Q-omics provides the consensus-scored TRAJ43 profile across patient tissues and cancer cell-line models. TRAJ43 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TRAJ43 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, TRAJ43 RNA expression shows 11,634 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, BRCA, and LSCC as cancer lineages where TRAJ43 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ43 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ43 survival associations across molecular data types. TRAJ43 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ43 RNA expression–survival associations across cancer types. High TRAJ43 expression shows unfavorable associations in KIRP, LGG, MESO and KIRC, but favorable associations in UCEC and TGCT. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TRAJ43 RNA expression.
This table summarizes TRAJ43 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ43. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ43 shows higher tumor expression in BRCA, KIRC and STAD. The BRCA box plot shows higher TRAJ43 RNA expression in tumor versus normal tissue (log2 FC = +0.222, t-test p = .003).
This table shows molecular features associated with TRAJ43 in patient tissues and cancer cell lines. In patient samples, TRAJ43 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
